Cronos Group
Investor Relations | The Cronos Group
  • Cronos Group (CRON) announced the launch of its first range of products, in partnership with Geocann
  • It will utilize the advanced VESIsorb delivery system to provide better bioavailability and faster absorption
  • Cronos cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach
  • Cronos Group Inc. (CRON) was down 0.99 per cent, trading at C$3.99 at 2.31 pm ET

Cronos Group (CRON) announced the launch of its first range of products in partnership with Geocann.

It will utilize the VESIsorb delivery system to provide better bioavailability and faster absorption. VESIsorb delivers superior pharmacokinetic performance, including rapid absorption, higher plasma concentration, and a greater area under the curve.

Mike Gorenstein, Chairman, President and Chief Executive Officer of Cronos commented on the news.

“Working with Geocann’s technology enables us to expand our product offering. It bring consumers a fast-acting cannabinoid product with a quicker onset than previously available. It improves efficacy, helping enhance and differentiate effect and experience.”

VESIsorb dramatically improves the bioavailability of difficult-to-absorb ingredients, like cannabinoids and terpenes. This patented technology has shown faster absorption in both well-designed pilot and peer-reviewed published studies.

Geocann is the exclusive supplier of the VESIsorb delivery system for cannabinoids, terpenes, and flavonoid formulations. The first VESIsorb formulated product the companies have launched is the CBD Gel Capsules by Lord Jones.

Cronos cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach.

Cronos Group Inc. (CRON) was down 0.99 per cent, trading at C$3.99 at 2.31 pm ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Buzz on the Bullboards: A recap of recent activity and stocks in focus

After a major sell-off, stock markets have been on edge, monitoring corporate earnings to gauge the direction of the economy.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.